NDA 213973 · Deciphera Pharms
Qinlock
Ripretinib · Oral · Kinase Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: May 6, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
May 15, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
12
3 Phase 3, 0 recruiting
FAERS reports
5,243
2,276 serious, 497 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 12, 2025.
QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ( 1 )
Mechanism: Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations. Ripretinib also inhibits other kinases in vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF.
Therapeutic areas: Oncology · Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 15, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- QINLOCK · RIPRETINIB 50MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ripretinib" as an intervention, any sponsor and status, largest first.
- A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibPivotal-lookingActive, not recruiting
Deciphera Pharmaceuticals, LLCIndustry
NCT03673501 · 453 participants · Start Feb 8, 2019 · Primary completion Sep 1, 2021
Drug: Ripretinib; Sunitinib · For: Gastrointestinal Stromal Tumors
Sites: Scottsdale, Arizona; La Jolla, California; Los Angeles, California · 121 sites in all
Deciphera Pharmaceuticals, LLCIndustry
NCT02571036 · 282 participants · Start Nov 2015 · Primary completion Apr 29, 2022
Drug: DCC-2618; DCC-2618 · For: Gastrointestinal Stromal Tumors; Advanced Systemic Mastocytosis; Advanced Cancers
Sites: Scottsdale, Arizona; Los Angeles, California; Palo Alto, California · 26 sites in all
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsActive, not recruiting
IDRX, Inc., a wholly owned subsidiary of GSK, LLCIndustry
NCT05489237 · 276 participants · Start Aug 3, 2022 · Primary completion Mar 10, 2027
Drug: IDRX-42 · For: Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumor (GIST); Digestive System Disease and 2 more
Sites: Miami, Florida; Chicago, Illinois; Boston, Massachusetts · 31 sites in all
- Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer TherapiesPivotal-lookingCompleted
Deciphera Pharmaceuticals, LLCIndustry
NCT03353753 · 129 participants · Start Feb 27, 2018 · Primary completion May 31, 2019
Drug: DCC-2618; Placebo Oral Tablet · For: Gastrointestinal Stromal Tumors
Sites: Scottsdale, Arizona; Los Angeles, California; Stanford, California · 35 sites in all
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibPivotal-lookingCompleted
Zai Lab (Shanghai) Co., Ltd.Industry
NCT04633122 · 108 participants · Start Nov 25, 2020 · Primary completion Jul 20, 2022
Drug: Ripretinib; Sunitinib · For: Gastrointestinal Stromal Tumor(GIST)
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 18 sites in all
- A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced MalignanciesActive, not recruiting
Deciphera Pharmaceuticals, LLCIndustry
NCT05957367 · 94 participants (planned) · Start Sep 28, 2023 · Primary completion Mar 2027
Drug: Inlexisertib; Ripretinib · For: GIST
Sites: Los Angeles, California; Miami, Florida; Worcester, Massachusetts · 28 sites in all
- A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With ImatinibPivotal-lookingActive, not recruiting
Deciphera Pharmaceuticals, LLCIndustry
NCT05734105 · 54 participants (planned) · Start Dec 13, 2023 · Primary completion Dec 2027
Drug: Ripretinib; Sunitinib · For: GIST
Sites: La Jolla, California; New Haven, Connecticut; Jacksonville, Florida · 70 sites in all
Zai Lab (Shanghai) Co., Ltd.Industry
NCT04282980 · 39 participants · Start Apr 23, 2020 · Primary completion Feb 26, 2021
Drug: DCC-2618 · For: Gastrointestinal Stromal Tumors
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue688
- alopecia594
- death381
- underdose374
- extra dose administered357
- nausea338
- drug ineffective334
- hospitalisation319
- disease progression298
- pain295
- constipation292
- diarrhoea279
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 303 |
| 2021 | 727 |
| 2022 | 833 |
| 2023 | 951 |
| 2024 | 842 |
| 2025 | 1,016 |
| 2026 | 571 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Qinlock (Ripretinib)
2024 spending
$78.7M
Beneficiaries
352
1,814 claims
Per beneficiary
$223,478
$454.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $16,379,736 |
| 2021 | $36,976,955 |
| 2022 | $44,753,132 |
| 2023 | $52,132,977 |
| 2024 | $78,664,212 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
Blay JY, Serrano C, Heinrich MC, et al. · Lancet Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
- Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
Heinrich MC, Jones RL, George S, et al. · Nat Med 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Bauer S, Jones RL, Blay JY, et al. · J Clin Oncol 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor.
Kumar V, Doros L, Thompson M, et al. · Clin Cancer Res 2023 · Randomized Controlled Trial, Research Support, N.I.H., Intramural
- Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
Sargsyan A, Kucharczyk MA, Jones RL, et al. · Expert Rev Gastroenterol Hepatol 2023 · Clinical Trial, Phase I, Clinical Trial, Phase III
- Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
Nemunaitis J, Bauer S, Blay JY, et al. · Future Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Deciphera Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.